NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Document Info
Form Name: NT 10-K
Filed: March 31, 2009
NT 10-K 1 bfnh033109nt10k.htm NOTIFICATION OF LATE FILING

(Check One):


x Form 10-K

[ ] Form  20-F

[ ] Form  11-K  

[ ] Form  10-Q

[ ] Form N-SAR





Washington, D.C. 20549


FORM 12b-25






SEC File Number:



    For Period Ended December 31, 2008
    [ ]  Transition Report on Form 10-K
    [ ]  Transition Report on Form 20-F
    [ ]  Transition Report on Form 11-K
    [ ] Transition Report on Form 10-Q
    [ ]Transition Report on Form N-SAR
    For the Transition Period Ended:                                                              



Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.



If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:





BioForce Nanosciences Holdings, Inc.

Full name of registrant


Silver River Ventures, Inc.

Former name if applicable


1615 Golden Aspen Drive, Suite 101

Address of principal executive office (Street and number)


Ames, Iowa 50010

City, state and zip code



PART II - RULES 12b-25(b) and (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)


x (a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c)   The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.





State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.


Our Annual Report on Form 10-K for the period ended December 31, 2008 cannot be filed within the prescribed time period because management has not been able to finalize, without unreasonable effort or expense, information and documents required for the completion of the audit of the Company's financial statements for the year ending December 31, 2008, by March 31, 2009.






(1) Name and telephone number of person to contact in regard to this notification:


Gregory D. Brown




(Area Code)


233-8333, ext.#118

(Telephone Number)


(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).    x  Yes      [ ]No




(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?     [ ]Yes    x  No


If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.



BioForce Nanosciences Holdings, Inc.

             (Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.


Date:   March 31, 2009  



/s/ Gregory D. Brown

            Gregory D. Brown
            Chief Financial Officer


INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.




Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).